Effect of Carbon Dioxide Enriched Ambient Air on Pharmacokinetics and Deposition In Bronchiectasis Patients Using Tobramycin Inhalation: A proof of concept study.

Completed

• Conditions: Bronchiëctasis; chronic lung damage; 10004018; 10024970

• Registration Number: NL-OMON41356
• Lead Sponsor: Vrije Universiteit Medisch Centrum

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 29 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 14

Inclusion Criteria

o Bronchiectasis.
o Antibiotic inhalation therapy

Exclusion Criteria

o Age <21 years.
o Chronic respiratory insufficiency defined according to the GOLD criteria (PaO2 < 60 mmHg or PaCO2 > 50 mmHg, WHO Global Initiative for Chronic Obstructive Lung Disease 2006)
o Renal insufficiency defined as renal creatinine clearance of < 30 ml/minute.
o Neuromuscular diseases.
o Impaired hearing
o Pregnant or breastfeeding.
o Bronchiectasis exacerbation during last 4 weeks.
o History of panic attacks.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>o Feasibility of SPECT/CT scans<br /><br>o Pulmonary deposition and pharmacokinetics </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>o Peak expiratory flow<br /><br>o Respiratory parameters<br /><br>o Borg score (subjective sensation of dyspnoea) </p><br>